Phase II Efficacy Trial Of Antex's Campylobacter Vaccine Announced
Spectrum Science CommunicationsAntex Biologics, SmithKline Beecham, and the United States Navy today jointly announced the start of a Phase II clinical trial for Antex's Campylobacter vaccine. This study will evaluate the efficacy of this oral vaccine against infectious Campylobacter, which causes 400-500 million cases of diarrhea annually.